TY - STD TI - Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. Mol Ther. 25(5): p. 1069–1075 ID - ref1 ER - TY - STD TI - FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. U.S. Food and Drug Administration news release 19th September 2016; Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm521263.htm UR - https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm521263.htm ID - ref2 ER - TY - STD TI - FDA approves first drug for spinal muscular atrophy. U.S. Food and Drug Administration news release 23 December 2016; Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm534611.htm UR - https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm534611.htm ID - ref3 ER - TY - JOUR AU - Sterne-Weiler, T. AU - Sanford, J. R. PY - 2014 DA - 2014// TI - Exon identity crisis: disease-causing mutations that disrupt the splicing code JO - Genome Biol VL - 15 UR - https://doi.org/10.1186/gb4150 DO - 10.1186/gb4150 ID - Sterne-Weiler2014 ER - TY - JOUR AU - Chan, J. H. AU - Lim, S. AU - Wong, W. S. PY - 2006 DA - 2006// TI - Antisense oligonucleotides: from design to therapeutic application JO - Clin Exp Pharmacol Physiol VL - 33 UR - https://doi.org/10.1111/j.1440-1681.2006.04403.x DO - 10.1111/j.1440-1681.2006.04403.x ID - Chan2006 ER - TY - JOUR AU - Khvorova, A. AU - Watts, J. K. PY - 2017 DA - 2017// TI - The chemical evolution of oligonucleotide therapies of clinical utility JO - Nat Biotech VL - 35 UR - https://doi.org/10.1038/nbt.3765 DO - 10.1038/nbt.3765 ID - Khvorova2017 ER - TY - JOUR AU - Evers, M. M. AU - Toonen, L. J. AU - van Roon-Mom, W. M. PY - 2015 DA - 2015// TI - Antisense oligonucleotides in therapy for neurodegenerative disorders JO - Adv Drug Deliv Rev VL - 87 UR - https://doi.org/10.1016/j.addr.2015.03.008 DO - 10.1016/j.addr.2015.03.008 ID - Evers2015 ER - TY - JOUR AU - McGarry, M. E. PY - 2017 DA - 2017// TI - In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies JO - Pediatr Pulmonol VL - 52 UR - https://doi.org/10.1002/ppul.23659 DO - 10.1002/ppul.23659 ID - McGarry2017 ER - TY - JOUR AU - Lillie, E. O. PY - 2011 DA - 2011// TI - The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? JO - Per Med VL - 8 UR - https://doi.org/10.2217/pme.11.7 DO - 10.2217/pme.11.7 ID - Lillie2011 ER - TY - JOUR AU - Williamson, S. F. PY - 2017 DA - 2017// TI - A Bayesian adaptive design for clinical trials in rare diseases JO - Comput Statist Data Anal VL - 113 UR - https://doi.org/10.1016/j.csda.2016.09.006 DO - 10.1016/j.csda.2016.09.006 ID - Williamson2017 ER - TY - JOUR AU - Schmidli, H. AU - Neuenschwander, B. AU - Friede, T. PY - 2017 DA - 2017// TI - Meta-analytic-predictive use of historical variance data for the design and analysis of clinical trials JO - Comput Stat Data Anal VL - 113 UR - https://doi.org/10.1016/j.csda.2016.08.007 DO - 10.1016/j.csda.2016.08.007 ID - Schmidli2017 ER - TY - JOUR AU - Crooke, S. T. PY - 2013 DA - 2013// TI - RNA directed therapeutics: mechanisms and status JO - Drug Discov Today Therapeutic Strateg VL - 10 UR - https://doi.org/10.1016/j.ddstr.2012.12.001 DO - 10.1016/j.ddstr.2012.12.001 ID - Crooke2013 ER - TY - JOUR AU - Crooke, S. T. PY - 2016 DA - 2016// TI - Integrated safety assessment of 2′-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers JO - Mol Ther VL - 24 UR - https://doi.org/10.1038/mt.2016.136 DO - 10.1038/mt.2016.136 ID - Crooke2016 ER - TY - JOUR AU - Burdick, A. D. PY - 2014 DA - 2014// TI - Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides JO - Nucleic Acids Res VL - 42 UR - https://doi.org/10.1093/nar/gku142 DO - 10.1093/nar/gku142 ID - Burdick2014 ER - TY - STD TI - Shen X, Corey DR (2017) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. [Epub ahead of print] ID - ref15 ER - TY - JOUR AU - Jarver, P. AU - O'Donovan, L. AU - Gait, M. J. PY - 2014 DA - 2014// TI - A chemical view of oligonucleotides for exon skipping and related drug applications JO - Nucleic Acid Ther VL - 24 UR - https://doi.org/10.1089/nat.2013.0454 DO - 10.1089/nat.2013.0454 ID - Jarver2014 ER - TY - JOUR AU - Bennett, C. F. AU - Swayze, E. E. PY - 2010 DA - 2010// TI - RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform JO - Annu Rev Pharmacol Toxicol VL - 50 UR - https://doi.org/10.1146/annurev.pharmtox.010909.105654 DO - 10.1146/annurev.pharmtox.010909.105654 ID - Bennett2010 ER - TY - JOUR AU - Dias, N. AU - Stein, C. A. PY - 2002 DA - 2002// TI - Antisense oligonucleotides: basic concepts and mechanisms JO - Mol Cancer Ther VL - 1 ID - Dias2002 ER - TY - JOUR AU - Agrawal, S. PY - 1995 DA - 1995// TI - Pharmacokinetics of antisense oligonucleotides JO - Clin Pharmacokinet VL - 28 UR - https://doi.org/10.2165/00003088-199528010-00002 DO - 10.2165/00003088-199528010-00002 ID - Agrawal1995 ER - TY - JOUR AU - Kole, R. AU - Vacek, M. AU - Williams, T. PY - 2004 DA - 2004// TI - Modification of alternative splicing by antisense therapeutics JO - Oligonucleotides VL - 14 UR - https://doi.org/10.1089/154545704322988067 DO - 10.1089/154545704322988067 ID - Kole2004 ER - TY - JOUR AU - Havens, M. A. AU - Hastings, M. L. PY - 2016 DA - 2016// TI - Splice-switching antisense oligonucleotides as therapeutic drugs JO - Nucleic Acids Res VL - 44 UR - https://doi.org/10.1093/nar/gkw533 DO - 10.1093/nar/gkw533 ID - Havens2016 ER - TY - JOUR AU - Stephenson, M. L. AU - Zamecnik, P. C. PY - 1978 DA - 1978// TI - Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide JO - Proc Natl Acad Sci U S A VL - 75 UR - https://doi.org/10.1073/pnas.75.1.285 DO - 10.1073/pnas.75.1.285 ID - Stephenson1978 ER - TY - JOUR AU - Donis-Keller, H. PY - 1979 DA - 1979// TI - Site specific enzymatic cleavage of RNA JO - Nucleic Acids Res VL - 7 UR - https://doi.org/10.1093/nar/7.1.179 DO - 10.1093/nar/7.1.179 ID - Donis-Keller1979 ER - TY - STD TI - Roehr B (1998) Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care 4(10):14–6 ID - ref24 ER - TY - BOOK AU - Wathion, N. PY - 2002 DA - 2002// TI - Public statement on Vitravene (fomivirsen). The European Agency for the Evaluation of Medical Products ID - Wathion2002 ER - TY - JOUR AU - Ng, E. W. M. PY - 2006 DA - 2006// TI - Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease JO - Nat Rev Drug Discov VL - 5 UR - https://doi.org/10.1038/nrd1955 DO - 10.1038/nrd1955 ID - Ng2006 ER - TY - JOUR AU - Wong, E. AU - Goldberg, T. PY - 2014 DA - 2014// TI - Mipomersen (Kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia JO - Pharm Ther VL - 39 ID - Wong2014 ER - TY - JOUR AU - Dominski, Z. AU - Kole, R. PY - 1993 DA - 1993// TI - Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides JO - Proc Natl Acad Sci U S A VL - 90 UR - https://doi.org/10.1073/pnas.90.18.8673 DO - 10.1073/pnas.90.18.8673 ID - Dominski1993 ER - TY - JOUR AU - Lacerra, G. PY - 2000 DA - 2000// TI - Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients JO - Proc Natl Acad Sci U S A VL - 97 UR - https://doi.org/10.1073/pnas.97.17.9591 DO - 10.1073/pnas.97.17.9591 ID - Lacerra2000 ER - TY - JOUR AU - Kipshidze, N. N. PY - 2002 DA - 2002// TI - Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model JO - J Am Coll Cardiol VL - 39 UR - https://doi.org/10.1016/S0735-1097(02)01830-2 DO - 10.1016/S0735-1097(02)01830-2 ID - Kipshidze2002 ER - TY - JOUR AU - Moreno, P. M. AU - Pego, A. P. PY - 2014 DA - 2014// TI - Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic JO - Front Chem VL - 2 UR - https://doi.org/10.3389/fchem.2014.00087 DO - 10.3389/fchem.2014.00087 ID - Moreno2014 ER - TY - JOUR AU - Castanotto, D. AU - Stein, C. A. PY - 2014 DA - 2014// TI - Antisense oligonucleotides in cancer JO - Curr Opin Oncol VL - 26 UR - https://doi.org/10.1097/CCO.0000000000000127 DO - 10.1097/CCO.0000000000000127 ID - Castanotto2014 ER - TY - JOUR AU - Riboldi, G. PY - 2014 DA - 2014// TI - Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases JO - Mol Neurobiol VL - 50 UR - https://doi.org/10.1007/s12035-014-8724-7 DO - 10.1007/s12035-014-8724-7 ID - Riboldi2014 ER - TY - JOUR AU - Aronin, N. AU - DiFiglia, M. PY - 2014 DA - 2014// TI - Huntingtin-lowering strategies in Huntington’s disease: antisense oligonucleotides, small RNAs, and gene editing JO - Mov Disord VL - 29 UR - https://doi.org/10.1002/mds.26020 DO - 10.1002/mds.26020 ID - Aronin2014 ER - TY - JOUR AU - Greer, K. L. PY - 2014 DA - 2014// TI - Targeted exon skipping to correct exon duplications in the dystrophin gene JO - Mol Ther Nucleic Acids VL - 3 UR - https://doi.org/10.1038/mtna.2014.8 DO - 10.1038/mtna.2014.8 ID - Greer2014 ER - TY - STD TI - Kinane TB, et al (2017) Long-term pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history. J Neuromuscul Dis. [Epub ahead of print] ID - ref36 ER - TY - STD TI - Sarepta Therapeutics, I., (2017) Sarepta Therapeutics announces positive results in its study evaluating gene expression, dystrophin production, and dystrophin localization in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 53 treated with golodirsen (SRP-4053), I. Estepan, Editor.: http://investorrelations.sarepta.com UR - http://investorrelations.sarepta.com ID - ref37 ER - TY - JOUR AU - Yokota, T. PY - 2007 DA - 2007// TI - Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy JO - Expert Opin Biol Ther VL - 7 UR - https://doi.org/10.1517/14712598.7.6.831 DO - 10.1517/14712598.7.6.831 ID - Yokota2007 ER - TY - JOUR AU - Adkin, C. F. PY - 2012 DA - 2012// TI - Multiple exon skipping strategies to by-pass dystrophin mutations JO - Neuromuscul Disord VL - 22 UR - https://doi.org/10.1016/j.nmd.2011.10.007 DO - 10.1016/j.nmd.2011.10.007 ID - Adkin2012 ER - TY - JOUR AU - Miskew Nichols, B. PY - 2016 DA - 2016// TI - Multi-exon skipping using cocktail antisense oligonucleotides in the canine X-linked muscular dystrophy JO - J Vis Exp VL - 111 ID - Miskew Nichols2016 ER - TY - JOUR AU - Wilton, S. D. PY - 2007 DA - 2007// TI - Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript JO - Mol Ther VL - 15 UR - https://doi.org/10.1038/sj.mt.6300095 DO - 10.1038/sj.mt.6300095 ID - Wilton2007 ER - TY - JOUR AU - Béroud, C. PY - 2007 DA - 2007// TI - Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy JO - Hum Mutat VL - 28 UR - https://doi.org/10.1002/humu.20428 DO - 10.1002/humu.20428 ID - Béroud2007 ER - TY - JOUR AU - Lefebvre, S. PY - 1995 DA - 1995// TI - Identification and characterization of a spinal muscular atrophy-determining gene JO - Cell VL - 80 UR - https://doi.org/10.1016/0092-8674(95)90460-3 DO - 10.1016/0092-8674(95)90460-3 ID - Lefebvre1995 ER - TY - JOUR AU - Lorson, C. L. PY - 1999 DA - 1999// TI - A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy JO - Proc Natl Acad Sci VL - 96 UR - https://doi.org/10.1073/pnas.96.11.6307 DO - 10.1073/pnas.96.11.6307 ID - Lorson1999 ER - TY - JOUR AU - Singh, N. K. PY - 2006 DA - 2006// TI - Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron JO - Mol Cell Biol VL - 26 UR - https://doi.org/10.1128/MCB.26.4.1333-1346.2006 DO - 10.1128/MCB.26.4.1333-1346.2006 ID - Singh2006 ER - TY - JOUR AU - Finkel, R. S. PY - 2016 DA - 2016// TI - Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study JO - Lancet VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31408-8 DO - 10.1016/S0140-6736(16)31408-8 ID - Finkel2016 ER - TY - JOUR AU - Paton, D. M. PY - 2017 DA - 2017// TI - Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy JO - Drugs Today (Barc) VL - 53 UR - https://doi.org/10.1358/dot.2017.53.6.2652413 DO - 10.1358/dot.2017.53.6.2652413 ID - Paton2017 ER - TY - JOUR AU - Ferec, C. AU - Cutting, G. R. PY - 2012 DA - 2012// TI - Assessing the disease-liability of mutations in CFTR JO - Cold Spring Harb Perspect Med VL - 2 UR - https://doi.org/10.1101/cshperspect.a009480 DO - 10.1101/cshperspect.a009480 ID - Ferec2012 ER - TY - JOUR AU - Kreindler, J. L. PY - 2010 DA - 2010// TI - Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies JO - Pharmacol Ther VL - 125 UR - https://doi.org/10.1016/j.pharmthera.2009.10.006 DO - 10.1016/j.pharmthera.2009.10.006 ID - Kreindler2010 ER - TY - STD TI - Rommens DJM (2011) CFTR Mutation Database. Hospital for Sick Children ID - ref50 ER - TY - JOUR AU - Welsh, M. J. AU - Smith, A. E. PY - 1993 DA - 1993// TI - Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis JO - Cell VL - 73 UR - https://doi.org/10.1016/0092-8674(93)90353-R DO - 10.1016/0092-8674(93)90353-R ID - Welsh1993 ER - TY - JOUR AU - Accurso, F. J. PY - 2010 DA - 2010// TI - Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa0909825 DO - 10.1056/NEJMoa0909825 ID - Accurso2010 ER - TY - JOUR AU - Van Goor, F. PY - 2009 DA - 2009// TI - Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 JO - Proc Natl Acad Sci VL - 106 UR - https://doi.org/10.1073/pnas.0904709106 DO - 10.1073/pnas.0904709106 ID - Van Goor2009 ER - TY - JOUR AU - Wainwright, C. E. PY - 2015 DA - 2015// TI - Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1409547 DO - 10.1056/NEJMoa1409547 ID - Wainwright2015 ER - TY - JOUR AU - Beumer, W. PY - 2015 DA - 2015// TI - WS01.2 QR-010, an RNA therapy, restores CFTR function using in vitro and in vivo models of ΔF508 CFTR JO - J Cyst Fibros VL - 14 UR - https://doi.org/10.1016/S1569-1993(15)30002-3 DO - 10.1016/S1569-1993(15)30002-3 ID - Beumer2015 ER - TY - JOUR AU - Zamecnik, P. C. PY - 2004 DA - 2004// TI - Reversal of cystic fibrosis phenotype in a cultured Delta508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion JO - Proc Natl Acad Sci U S A VL - 101 UR - https://doi.org/10.1073/pnas.0401933101 DO - 10.1073/pnas.0401933101 ID - Zamecnik2004 ER - TY - JOUR AU - Massie, R. J. PY - 2001 DA - 2001// TI - Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C JO - Eur Respir J VL - 17 UR - https://doi.org/10.1183/09031936.01.00057001 DO - 10.1183/09031936.01.00057001 ID - Massie2001 ER - TY - JOUR AU - Radpour, R. PY - 2007 DA - 2007// TI - Molecular study of (TG)m(T)n polymorphisms in Iranian males with congenital bilateral absence of the vas deferens JO - J Androl VL - 28 UR - https://doi.org/10.2164/jandrol.106.002337 DO - 10.2164/jandrol.106.002337 ID - Radpour2007 ER - TY - JOUR AU - Chu, C. S. PY - 1991 DA - 1991// TI - Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium JO - EMBO J VL - 10 ID - Chu1991 ER - TY - JOUR AU - Igreja, S. PY - 2016 DA - 2016// TI - Correction of a cystic fibrosis splicing mutation by antisense oligonucleotides JO - Hum Mutat VL - 37 UR - https://doi.org/10.1002/humu.22931 DO - 10.1002/humu.22931 ID - Igreja2016 ER - TY - JOUR AU - Quint, A. PY - 2005 DA - 2005// TI - Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening JO - Am J Med Genet A VL - 136 UR - https://doi.org/10.1002/ajmg.a.30823 DO - 10.1002/ajmg.a.30823 ID - Quint2005 ER - TY - JOUR AU - Friedman, K. J. PY - 1999 DA - 1999// TI - Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides JO - J Biol Chem VL - 274 UR - https://doi.org/10.1074/jbc.274.51.36193 DO - 10.1074/jbc.274.51.36193 ID - Friedman1999 ER - TY - JOUR AU - Highsmith, W. E. PY - 1994 DA - 1994// TI - A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations JO - N Engl J Med VL - 331 UR - https://doi.org/10.1056/NEJM199410133311503 DO - 10.1056/NEJM199410133311503 ID - Highsmith1994 ER - TY - JOUR AU - Griese, M. PY - 1999 DA - 1999// TI - Pulmonary surfactant in health and human lung diseases: state of the art JO - Eur Respir J VL - 13 UR - https://doi.org/10.1183/09031936.99.13614779 DO - 10.1183/09031936.99.13614779 ID - Griese1999 ER - TY - JOUR AU - Wert, S. E. AU - Whitsett, J. A. AU - Nogee, L. M. PY - 2009 DA - 2009// TI - Genetic disorders of surfactant dysfunction JO - Pediatr Dev Pathol VL - 12 UR - https://doi.org/10.2350/09-01-0586.1 DO - 10.2350/09-01-0586.1 ID - Wert2009 ER - TY - JOUR AU - Whitsett, J. A. AU - Wert, S. E. AU - Weaver, T. E. PY - 2015 DA - 2015// TI - Diseases of pulmonary surfactant homeostasis JO - Annu Rev Pathol VL - 10 UR - https://doi.org/10.1146/annurev-pathol-012513-104644 DO - 10.1146/annurev-pathol-012513-104644 ID - Whitsett2015 ER - TY - JOUR AU - Gupta, A. AU - Zheng, S. L. PY - 2017 DA - 2017// TI - Genetic disorders of surfactant protein dysfunction: when to consider and how to investigate JO - Arch Dis Child VL - 102 UR - https://doi.org/10.1136/archdischild-2012-303143 DO - 10.1136/archdischild-2012-303143 ID - Gupta2017 ER - TY - JOUR AU - Gower, W. A. AU - Nogee, L. M. PY - 2011 DA - 2011// TI - Surfactant dysfunction JO - Paediatr Respir Rev VL - 12 UR - https://doi.org/10.1016/j.prrv.2011.01.005 DO - 10.1016/j.prrv.2011.01.005 ID - Gower2011 ER - TY - JOUR AU - Faro, A. AU - Hamvas, A. PY - 2008 DA - 2008// TI - Lung transplantation for inherited disorders of surfactant metabolism JO - NeoReviews VL - 9 UR - https://doi.org/10.1542/neo.9-10-e468 DO - 10.1542/neo.9-10-e468 ID - Faro2008 ER - TY - JOUR AU - Hamvas, A. PY - 2010 DA - 2010// TI - Evaluation and management of inherited disorders of surfactant metabolism JO - Chin Med J VL - 123 ID - Hamvas2010 ER - TY - JOUR AU - Williamson, M. AU - Wallis, C. PY - 2014 DA - 2014// TI - Ten-year follow up of hydroxychloroquine treatment for ABCA3 deficiency JO - Pediatr Pulmonol VL - 49 UR - https://doi.org/10.1002/ppul.22811 DO - 10.1002/ppul.22811 ID - Williamson2014 ER - TY - JOUR AU - Don Hayes, J. PY - 2012 DA - 2012// TI - ABCA3 transporter deficiency JO - Am J Respir Crit Care Med VL - 186 UR - https://doi.org/10.1164/ajrccm.186.8.807 DO - 10.1164/ajrccm.186.8.807 ID - Don Hayes2012 ER - TY - JOUR AU - de Benedictis, F. M. AU - Bush, A. PY - 2012 DA - 2012// TI - Corticosteroids in respiratory diseases in children JO - Am J Respir Crit Care Med VL - 185 UR - https://doi.org/10.1164/rccm.201107-1174CI DO - 10.1164/rccm.201107-1174CI ID - de Benedictis2012 ER - TY - JOUR AU - Wambach, J. A. PY - 2014 DA - 2014// TI - Genotype-phenotype correlations for infants and children with ABCA3 deficiency JO - Am J Respir Crit Care Med VL - 189 UR - https://doi.org/10.1164/rccm.201402-0342OC DO - 10.1164/rccm.201402-0342OC ID - Wambach2014 ER - TY - JOUR AU - Agrawal, A. PY - 2012 DA - 2012// TI - An intronic ABCA3 mutation that is responsible for respiratory disease JO - Pediatr Res VL - 71 UR - https://doi.org/10.1038/pr.2012.21 DO - 10.1038/pr.2012.21 ID - Agrawal2012 ER - TY - JOUR AU - Nogee, L. M. PY - 2002 DA - 2002// TI - Abnormal expression of surfactant protein C and lung disease JO - Am J Respir Cell Mol Biol VL - 26 UR - https://doi.org/10.1165/ajrcmb.26.6.f241 DO - 10.1165/ajrcmb.26.6.f241 ID - Nogee2002 ER - TY - JOUR AU - Wang, W. -. J. PY - 2002 DA - 2002// TI - Biosynthesis of surfactant protein C (SP-C): sorting of SP-C proprotein involves homomeric association via a signal anchor domain JO - J Biol Chem VL - 277 UR - https://doi.org/10.1074/jbc.M201537200 DO - 10.1074/jbc.M201537200 ID - Wang2002 ER - TY - JOUR AU - Mulugeta, S. PY - 2005 DA - 2005// TI - A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation JO - Am J Respir Cell Mol Biol VL - 32 UR - https://doi.org/10.1165/rcmb.2005-0009OC DO - 10.1165/rcmb.2005-0009OC ID - Mulugeta2005 ER - TY - JOUR AU - Geary, R. S. PY - 2015 DA - 2015// TI - Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides JO - Adv Drug Deliv Rev VL - 87 UR - https://doi.org/10.1016/j.addr.2015.01.008 DO - 10.1016/j.addr.2015.01.008 ID - Geary2015 ER - TY - JOUR AU - Moschos, S. A. PY - 2011 DA - 2011// TI - Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense JO - Mol Ther VL - 19 UR - https://doi.org/10.1038/mt.2011.206 DO - 10.1038/mt.2011.206 ID - Moschos2011 ER - TY - JOUR AU - Moschos, S. A. PY - 2008 DA - 2008// TI - Targeting the lung using siRNA and antisense based oligonucleotides JO - Curr Pharm Des VL - 14 UR - https://doi.org/10.2174/138161208786898851 DO - 10.2174/138161208786898851 ID - Moschos2008 ER - TY - JOUR AU - Moschos, S. A. AU - Usher, L. AU - Lindsay, M. A. PY - 2017 DA - 2017// TI - Clinical potential of oligonucleotide-based therapeutics in the respiratory system JO - Pharmacol Ther VL - 169 UR - https://doi.org/10.1016/j.pharmthera.2016.10.009 DO - 10.1016/j.pharmthera.2016.10.009 ID - Moschos2017 ER - TY - JOUR AU - Fey, R. A. PY - 2014 DA - 2014// TI - Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-alpha delivery by inhalation in mouse and monkey JO - Inhal Toxicol VL - 26 UR - https://doi.org/10.3109/08958378.2014.907587 DO - 10.3109/08958378.2014.907587 ID - Fey2014 ER - TY - JOUR AU - Karras, J. G. PY - 2007 DA - 2007// TI - Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice JO - Am J Respir Cell Mol Biol VL - 36 UR - https://doi.org/10.1165/rcmb.2005-0456OC DO - 10.1165/rcmb.2005-0456OC ID - Karras2007 ER - TY - JOUR AU - Lach-Trifilieff, E. PY - 2001 DA - 2001// TI - In vitro and in vivo inhibition of interleukin (IL)-5-mediated eosinopoiesis by murine IL-5Ralpha antisense oligonucleotide JO - Am J Respir Cell Mol Biol VL - 24 UR - https://doi.org/10.1165/ajrcmb.24.2.4237 DO - 10.1165/ajrcmb.24.2.4237 ID - Lach-Trifilieff2001 ER - TY - JOUR AU - Duan, W. PY - 2005 DA - 2005// TI - Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice JO - Am J Respir Crit Care Med VL - 171 UR - https://doi.org/10.1164/rccm.200408-1006OC DO - 10.1164/rccm.200408-1006OC ID - Duan2005 ER - TY - JOUR AU - Crosby, J. R. PY - 2007 DA - 2007// TI - Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice JO - J Pharmacol Exp Ther VL - 321 UR - https://doi.org/10.1124/jpet.106.119214 DO - 10.1124/jpet.106.119214 ID - Crosby2007 ER - TY - JOUR AU - Yin, H. PY - 2014 DA - 2014// TI - Non-viral vectors for gene-based therapy JO - Nat Rev Genet VL - 15 UR - https://doi.org/10.1038/nrg3763 DO - 10.1038/nrg3763 ID - Yin2014 ER - TY - JOUR AU - Mologni, L. AU - Nielsen, P. E. AU - Gambacorti-Passerini, C. PY - 1999 DA - 1999// TI - In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid JO - Biochem Biophys Res Commun VL - 264 UR - https://doi.org/10.1006/bbrc.1999.1548 DO - 10.1006/bbrc.1999.1548 ID - Mologni1999 ER - TY - JOUR AU - Zhao, J. AU - Feng, S. S. PY - 2015 DA - 2015// TI - Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents JO - Nanomedicine (Lond) VL - 10 UR - https://doi.org/10.2217/nnm.15.61 DO - 10.2217/nnm.15.61 ID - Zhao2015 ER - TY - JOUR AU - Yang, Q. PY - 2014 DA - 2014// TI - Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation JO - Mol Pharm VL - 11 UR - https://doi.org/10.1021/mp400703d DO - 10.1021/mp400703d ID - Yang2014 ER - TY - JOUR AU - Juliano, R. L. PY - 2016 DA - 2016// TI - The delivery of therapeutic oligonucleotides JO - Nucleic Acids Res VL - 44 UR - https://doi.org/10.1093/nar/gkw236 DO - 10.1093/nar/gkw236 ID - Juliano2016 ER - TY - STD TI - Ugarte-Uribe B, et al (2016) Lipid-modified oligonucleotide conjugates: insights into gene silencing, interaction with model membranes and cellular uptake mechanisms. Bioorg Med Chem 25(1):175–186 ID - ref93 ER - TY - JOUR AU - Alam, M. R. PY - 2008 DA - 2008// TI - Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis JO - Nucleic Acids Res VL - 36 UR - https://doi.org/10.1093/nar/gkn115 DO - 10.1093/nar/gkn115 ID - Alam2008 ER - TY - JOUR AU - Dassie, J. P. AU - Giangrande, P. H. PY - 2013 DA - 2013// TI - Current progress on aptamer-targeted oligonucleotide therapeutics JO - Ther Deliv VL - 4 UR - https://doi.org/10.4155/tde.13.118 DO - 10.4155/tde.13.118 ID - Dassie2013 ER - TY - JOUR AU - Lu, Q. L. PY - 2003 DA - 2003// TI - Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse JO - Nat Med VL - 9 UR - https://doi.org/10.1038/nm897 DO - 10.1038/nm897 ID - Lu2003 ER - TY - JOUR AU - Han, G. PY - 2016 DA - 2016// TI - Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms10981 DO - 10.1038/ncomms10981 ID - Han2016 ER - TY - JOUR AU - Crooke, S. T. PY - 2017 DA - 2017// TI - Cellular uptake and trafficking of antisense oligonucleotides JO - Nat Biotechnol VL - 35 UR - https://doi.org/10.1038/nbt.3779 DO - 10.1038/nbt.3779 ID - Crooke2017 ER -